72
Participants
Start Date
October 3, 2022
Primary Completion Date
April 10, 2025
Study Completion Date
April 10, 2025
Placebo
0.9 percent sodium chloride
WRAIR-PAM-CF1
Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
Northwell Health, New Hyde Park
Johns Hopkins University, Baltimore
University of South Florida/Tampa General Hospital, Tampa
University of Virginia, Charlottesville
Duke University Medical Center, Durham
Emory University - Adult Cystic Fibrosis Program, Atlanta
Case Western Reserve University, Cleveland
Michigan Medicine, Ann Arbor
University of Texas Southwestern Medical Center, Dallas
University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles
University of California, San Diego, La Jolla
Stanford University, Stanford
University of California Davis Health, Sacramento
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson
Yale North Haven Medical Center- Winchester Center for Lung Disease, North Haven
University of Minnesota Medical Center, Minneapolis
Baylor College of Medicine, Houston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH